German pharmaceutical giant Merck KGaA (ETR: MRK) has announced the commencement of commercial manufacturing of its first Good Manufacturing Practice (GMP) compliant cell culture medium (CCM) production line in China. This strategic expansion into the Chinese market is a response to the growing demand for high-quality, customized CCM solutions.
Merck’s latest investment of EUR 6.6 million in the Nantong manufacturing facility is aimed at bolstering its production capabilities to cater to the specific needs of the Chinese biopharmaceutical industry. This move underscores Merck’s commitment to supporting the local life science community with advanced manufacturing technologies and solutions.- Flcube.com
